Strategic Partnerships Liquidia collaborates with patient advocacy programs and disease-focused partnerships (e.g., Team Phenomenal Hope and LMBYL) to advance patient support alongside its therapeutic development, presenting opportunities to co-market, sponsor events, or align with access programs for pulmonary hypertension therapies.

Clinical Expansion Active and upcoming clinical work around YUTREPIA and L606, plus presentations at major conferences, indicate ongoing pipeline growth and potential for expansion into additional pulmonary vascular indications or related respiratory diseases, offering cross-sell or line-extension discussions with payers and specialty distributors.

Manufacturing Upside Recent $50M manufacturing investment and leased facilities suggest capacity expansion to support launch execution and scale, creating opportunities to discuss contract development and manufacturing organization (CDMO) partnerships, supply chain resilience, and expedited production for new formulations.

Intellectual Property Vigilance Patent-related litigation activity, such as the United Airlines suit over Treprostinil DPI, signals a competitive IP environment; BD conversations can address licensing strategies, risk mitigations, and strategic alliances to secure market access and protect differentiating technologies.

Financial and Market Position Revenue in the tens of millions with a focused niche in pulmonary disease positions Liquidia as a targeted growth partner for specialty pharma, contract manufacturing, and distribution channels seeking innovative inhalation therapies for PAH and PH-ILD, especially in North America.